PharmaShots | Incisive News in 3 Shots

Subscribe Now

cytokine Storm

Novartis and Incyte Intend to Initiate the P-III RUXCOVID Study of Jakavi (ruxolitinib) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

Novartis and Incyte Intend to Initiate the P-III RUXCOVID Study of Jakavi (ruxolitinib) as a Treatment for Patients with COVID-19...

April 3, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us